Further to the announcement on 11 March 2025, Synairgen plc (AIM: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that, at the General Meeting held earlier today, both resolutions as set out in the Circular dated 11 March 2025, were duly passed by shareholders on a poll.

In accordance with Resolution 2 cancellation from AIM is expected to become effective at 7am on 9th April 2025 with the last day of dealings set to be the 8th April 2025. Admission to the Asset Match Private Market is expected to be on the 9th April 2025. 

The full announcement from Synairgen can be found here.

If you would like to be added to Asset Match's distribution list to receive updates on Synairgen, then please register on www.assetmatch.com or email dealing@assetmatch.com